SIMIAN VIRUS 40 (SV40)

Table of contents :

---

Epidemiology Genomics Proteomics Transmission Symptoms & signs Laboratory examinations

---

Epidemiology : prevalence of serum antibodies = 3.8% (< 5% in any age group). SV40 seroprevalence rates in the general populations of the USA and other countries have ranged from 2 to 20%^{ref1, ref2}. However, differences in the methodology and low sensitivity of the assays used in some studies make it difficult to ascertain the actual prevalence of SV40 infections. A report by Shah et al.^ref found that 18% of adult kidney transplant patients had specific neutralizing antibody to SV40. Another study among adult patients showed the presence of SV40 neutralizing antibodies in 16% of HIV-infected patients and 11% of individuals not infected with HIV^ref. Among hospitalized children, the overall prevalence of specific SV40 serum neutralizing antibodies was 6%^ref; the SV40 seropositivity among children increased with age (P = 0.01) and was significantly associated with kidney transplantation (P < 0.001). Recently, a study of the prevalence of SV40 infections showed rates of 9% in Hungary and 4% in the Czech Republic^ref. Females had a higher rate of SV40 antibodies than males, reaching 16% in Hungary and 8% in the Czech Republic in certain age groups. SV40 infections were found in similar proportions in both countries among persons not exposed to potentially contaminated polio vaccines and in subjects vaccinated in the era of SV40-free vaccines. Minor et al.^ref recently analyzed over 2,000 sera from the United Kingdom and found an SV40 seroprevalence rate of just under 5%. Most of the neutralizing titers were low, and there was no apparent relationship between antibody positivity and polio vaccine usage. These data suggest that SV40 is being transmitted in the human population today, probably at a relatively low prevalence rate. However, conclusions about seroprevalence rates should be viewed with caution, as very little is known about the human immune response to SV40 infections. Molecular studies of adult patients with renal disease and recipients of kidney transplants found that SV40 cytopathic effects developed in CV-1 cells cocultured with urinary cells or PBMCs from those patients^{ref1, ref2}. SV40 sequences were detected by PCR in kidney biopsies from 56% of patients with focal segmental glomerulosclerosis (FSGS) (found also in brain and urine)^{ref1, ref2}. SV40 DNA was localized to renal tubular epithelial cell nuclei in renal biopsies of patients with FSGS as determined by in situ hybridization. In addition, studies showed that SV40 DNA sequences from the viral regulatory region were detected and identified in the allografts of immunocompromised pediatric renal transplants recipients^{ref1, ref2} and in the native kidney of a young adult lung transplant patient with polyomavirus nephropathy^ref. Different studies have detected SV40 DNA sequences in PBMCs from various patient populations^{ref1, ref2, ref3, ref4, ref5, ref6}. These results demonstrate the nephrotropic and lymphotropic properties of SV40 and indicate that the kidney can serve as a reservoir for the virus in humans. It appears that patients with acquired and/or iatrogenic immunosuppression are a population at risk for SV40. However, the frequency, natural history, and morbidity of the virus in this increasing patient population are unclear. Large prospective studies using sensitive and specific reagents for SV40 are needed to determine the prevalence of viral infections in the general population and to define groups of individuals at elevated risk for this emerging pathogen. Similarly important is the need for prospective longitudinal studies that address the morbidity and related mortality of these infections. The use of serologic tests alone may not be the most reliable way to conduct these studies. An enzyme immunoassay method for detection of SV40 antibodies in humans recognizes cross-reactivity between SV40, BKV, and JCV, complicating interpretation of assay results^ref. Similar limitations have been found in serologic methods for identification of human infection with herpes B virus (Cercopithecine herpesvirus 1), which is known also to naturally infect rhesus macaques (M. mulatta)^ref. Because infection with B virus in humans results in fatal encephalomyelitis or severe neurologic impairment, rapid and conclusive diagnosis is critical in order to control sequelae by this viral pathogen. Serologic assays (including enzyme immunoassay) for B-virus infection in humans are limited by low sensitivity and specificity^ref. Currently, cell culture for the 3 polyomaviruses known to infect humans (JCV, BKV, and SV40) is rarely helpful in establishing diagnosis of infection because of slow viral growth and the requirement for specialized cell lines^ref. Serologic assays may be useful for retrospective epidemiological analysis, but they are of minimal use for diagnosis or therapeutic decisions because most overt polyomavirus infections are believed to result from reactivation of latent infections^ref. Therefore, the use of modern molecular biology assays is an excellent and preferred alternative for the analysis of SV40 infections in the human population^ref. In addition, these sensitive and specific techniques are able to provide insights into the possible infectious etiology of human malignancies^{ref1, ref2, ref3}. Timeline :

• 1970s-1980s pre-PCR: SV40 and brain cancers
• 1992 SV40 DNA (PCR) and expression of large T-ag in brain cancers
• 1994 SV40 DNA and expression of large T-ag in malignant mesotheliomas
• 1995 Infectious SV40 isolated from a brain cancer of a 4-year-old child
• 1996 SV40 DNA in bone cancers
• 2002 SV40 DNA in lymphomas
• 2002 Institute of Medicine concluded that "SV40 exposure could lead to cancer in humans under natural conditions"

Genomics : SV40 shares 70% homology with JCV and BKV. Although these viruses are related, they can be distinguished easily at the DNA and protein levels. Genetic differences, particularly in the noncoding, regulatory regions of the viral genomes, may determine important differences in host range. Furthermore, the 3 viruses can be differentiated serologically by neutralization and hemagglutination assays^ref. The circular SV40 DNA genome is represented, with the unique EcoRI site shown at map unit 100/0. Nucleotide numbers based on reference strain SV40-776 begin and end at the origin (Ori) of viral DNA replication (map unit 0/5243). The ORFs that encode viral proteins are indicated. The early T-ag proteins are shown on the right, and the late structural (VP) proteins are shown on the left. The beginning and end of each open reading frame are indicated by nucleotide numbers^ref

It integrates into adenovirus/SV40 integration site 1 (ASVS1) :

• transcription factor CP2 (TFCP2) recognizes sites within SV40 late promoters
• transcription factor AP-2a (TFAP2A) and TEA domain family member 1 (TEAD1) / SV40 transcriptional enhancer factor bind to a consensus DNA-binding sequence CCCCAGGC in the SV40 promoter
• Sp1 transcription factor recruits SV40 capsid proteins to the viral packaging signal, ses : a molecular model suggests a VP1(5)-VP2/3-DNA-Sp1 complex
• SVmiRNAs accumulate at late times in infection, are perfectly complementary to early viral mRNAs, and target those mRNAs for cleavage. This reduces the expression of viral T antigens but does not reduce the yield of infectious virus relative to that generated by a mutant lacking SVmiRNAs. However, wild-type SV40-infected cells are less sensitive than the mutant to lysis by cytotoxic T cells, and trigger less cytokine production by such cells. Thus, viral evolution has taken advantage of the miRNA pathway to generate effectors that enhance the probability of successful infection^ref.

Proteomics : the SV40 genome is divided into :

• early region, coding for :
• 17 kDa small T-antigen is not essential for virus replication in tissue culture, and there is not a uniform requirement for it in SV40 transformation or tumor induction. However, studies indicate that SV40 small T-ag enhances large T-ag-mediated transformation^ref and is required for complete transformation of human cells in vitro^ref. It inhibits cellular PP2A by complexing with the catalytic subunit and regulatory subunit of the enzyme. Small T-ag plays a role in the induction of telomerase in SV40-infected human mesothelial cells^ref. Also, recent data indicate that small T-ag is required by large T-ag to upregulate Notch1 expression in SV40-infected and -transformed human mesothelial cells, as well as in SV40-positive human mesotheliomas^ref.
• 94 kDa large T antigen of SV40 strain 776 contains 708 amino acids and is a very multifunctional protein. The large T-ag is an essential replication protein that is required for initiation of viral DNA synthesis and that also stimulates host cells to enter S phase and undergo DNA synthesis. Because of this ability to subvert cell cycle control, T-ag represents the major transforming protein of SV40. T-ag forms complexes with several cellular proteins; fundamental to T-ag effects on host cells is binding to cellular tumor suppressor proteins^{ref1, ref2, ref3, ref4}.
• SV40 T-ag binding sequesters p53, abolishing its function and allowing cells with genetic damage to survive and enter S phase, leading to an accumulation of T-ag-expressing cells with genomic mutations that may promote tumorigenic growth
• pRb normally binds transcription factor E2F in early G₁ of the cell cycle; T-ag causes unscheduled dissociation of pRb/E2F complexes, releasing E2F to activate expression of growth-stimulatory genes^{ref1, ref2}
• T-ag interacts with karyopherin a₄ (importin a₃) and karyopherin a₂, downregulates developmentally regulated GTP binding protein 2 (DRG2), and recruits PP2A in a DNA J domain-dependent manner to reduce the phosphorylation of RBL2 / p130^ref.
These properties help explain SV40's potential as a tumor virus. However, it is important to point out that the oncogenic capacity of SV40 is an accidental side effect of the viral replication strategy; viral proteins (large and small T-ags) in lytically infected cells stimulate host cells into a state capable of supporting viral replication. Known T-ag functions are identified in boxes above and below the shaded bar, which represents the T-ag protein. The numbers given are amino acid residues based on reference strain SV40-776. The variable domain at the extreme C terminus contains amino acid differences among viral strains and is used for strain identification^ref

SV40 large T-ag variable domains. (a) Schematic of large T-ag, showing the location of the variable domain. (b) Amino acid changes in the T-ag C-terminal variable domains of representative SV40 isolates and human primary brain tumor-associated sequences, compared to that of SV40-776. The rectangular boxes represent the T-ag C-terminal region from amino acid (aa) 622 to 708. Virus isolates from monkey kidney cells are shown in the left column. Human brain isolates and primary brain cancer-associated sequences are in the right column. The numbering is according to the system for SV40-776. Del., deletion; Ins., insertion. Arrows indicate the positions and types of amino acid changes^ref

Although the function of the SV40 T-ag variable domain is not known, experimental data have suggested that it may be important in some aspect of the virus-host interaction. Embedded within the variable domain of large T-ag is a functional domain, which encompasses amino acids 682 to 708, defined as the host range/adenovirus helper function (hr/hf) domain. A C-terminal fragment of T-ag can relieve the adenovirus replication block in monkey cells^{ref1, ref2, ref3, ref4, ref5} by an unknown mechanism. The hr function was identified because T-ag C-terminal deletion mutants exhibited different growth properties in monkey cell lines; the deletion mutants grew very poorly in CV-1 cells but grew well in BSC and Vero cells^{ref1, ref2, ref3, ref4}. Viral DNA was replicated to near-wild-type levels in all three cell types^{ref1, ref2}. Virions produced by the hr/hf mutants do not assemble properly, seemingly due to an inability to add VP1 to the 75S assembly intermediates^ref. The helicase-active form of large tumor antigen is a ring-shaped hexamer/double hexamer, which has a positively charged hexameric channel for interacting with DNA. On the hexameric channel surface are 6 b-hairpin structures and loops, emanating from each of the 6 subunits. At the tips of the -hairpin and the loop structures are 2 ring-shaped residues, H513 and F459, respectively. Additionally, 2 positively charged residues, K512 and K516, are near the tip of the b-hairpin. The positions of these ring-shaped and positively charged residues suggest that they may play a role in binding DNA for helicase function. To understand the roles of these residues in helicase function, a set of mutants was obtained and various activities, including oligomerization, ATPase, DNA binding, and helicase activities, were examined. Substitution of these residues by Ala abolished helicase activity. Extensive mutagenesis showed that substitutions by ring-shaped residues (W and Y) at position F459 and by residues with hydrophobic or long aliphatic side chains (W, Y, F, L, M, and R) at position H513 supported helicase activity. The 4 residues (F459, H513, K512, and K516) play a critical role in interacting with DNA for helicase function. The results suggest a possible mechanism to explain how these residues, as well as the b-hairpin and the loop structures on which the residues reside, participate in binding and translocating DNA for origin melting and unwinding^ref.
• late region, coding for capsid proteins :
• VP1
• VP2
• VP3

There is only one known serotype of SV40, but genetic strains exist and can be distinguished by nucleotide differences in the regulatory region^ref and in the variable domain at the extreme C terminus of T-ag, which is defined as the last 86 amino acids of the molecule (residues 622 to 708)^{ref1, ref2, ref3, ref4, ref5, ref6, ref7}. Nucleotide differences in the T-ag C-terminal region, including polynucleotide insertions and deletions as well as single nucleotide changes, would change some encoded amino acids. These distinctions at the nucleotide and protein levels have conclusively established that SV40 sequences in human malignancies and other clinical samples are not the result of accidental laboratory contamination. However, future studies need to determine whether SV40 strains differ in pathogenic and/or oncogenic capacity. The classic example of DNA virus strains differing in oncogenic capacity is the HPV group; of the > 75 types described, of which about 30 cause genital infections, only a few types are associated with the development of cervical carcinoma^ref. This identification of high-risk strains has led to the development of preventive interventions, such as the vaccine against HPV type 16^ref.
Laboratory-adapted monkey strains of SV40 typically contain 2 72-bp enhancer elements; these are designated "nonarchetypal" or complex regulatory structures^ref. In contrast, SV40 isolates from human nonmalignant and malignant specimens usually (but not always) contain no duplications in the enhancer ("archetypal" structure). DNA sequence profiles of SV40 regulatory regions detected in human kidney transplant recipients. Ori, viral origin of DNA replication region, which spans nucleotides 5195 to 31; 21-bp repeats, GC-rich region between nucleotides 40 and 103; 72, 72-bp sequence within the enhancer region that is duplicated in some monkey strains (e.g., reference strain SV40-776). Nucleotide numbers are based on SV40-776. Shown are viral sequences associated with transplanted human kidneys (clone designations are on the right). Polymorphisms at the indicated residues are indicated above the boxes^ref. For a detailed description of the SV40 regulatory region^ref.

Regulatory region of SV40. DNA sequence profiles of regulatory regions of SV40 isolates from monkeys and humans and of human tumor-associated DNAs are shown. The diagrams are labeled as described in the legend to Fig. 4. Shown are laboratory-adapted strains (SV40-776, Baylor, and VA45-54), human isolates (SVCPC/SVMEN and SVPML-1), and viral sequences found associated with human brain (CPT, CPP, CPC, and Ep) and bone (Ost) tumors. Tumor-associated sequences usually contain a simple (archetypal) regulatory region without duplications in the enhancer region^ref.

An appreciation of the replication cycle of SV40 is fundamental to understanding the oncogenic capacity of SV40 and its potential etiologic role in some human malignancies. The MHC class I molecules are the specific cell surface receptors for SV40^{ref1, ref2}. This initial step in the viral cycle helps explain the broad tropism of the virus and its ability to infect and induce transformation in many types of cells and tissues. In addition, it provides an important distinction between SV40 and the other 2 polyomaviruses that are able to infect humans, JCV and BKV. JCV uses an N-linked glycoprotein and BKV uses a glycolipid as unique host cell receptors. These marked differences are believed to affect the nature of infections by these 3 viruses in tissues and individuals. After infection of a cell, SV40 produces large and small T-ags early in the viral replication cycle. These antigens bind and block important tumor suppressor proteins, which include p53, pRb, p107, and p130/Rb2^{ref1, Lednicky, J. A, 153-164, ref3}. The functions of these intracellular proteins are centered in the control of the cell cycle. The tumor suppressor p53 is believed to sense DNA damage and either pauses the cell in late G₁ for DNA repair or directs the cell to commit suicide through the apoptotic pathway^{ref1, ref2}. Therefore, SV40 infections in humans may interfere with several pathways related to cell cycle control and lead to development of malignancies. Studies indicate that SV40 can replicate productively in human cells, including fetal tissues^ref, newborn kidney cells^ref, and different human tumor cell lines^ref, although it grows poorly in human fibroblasts^ref. Moreover, in vitro assays have shown that human cells can support replication of SV40, establishing that human proteins have the intrinsic ability to cooperate with SV40 T-ag to replicate SV40 DNA^{ref1, ref2, ref3}. Some human cell types undergo visible cell lysis in response to SV40, whereas others fail to exhibit cytopathic changes and produce low levels of virus^ref. General conclusions from these early studies are that SV40 can replicate in human cells and that various human cell types display differences in susceptibility to infection by SV40. The basis for the differences is unknown, but T-ag functions are believed to be important^{ref1, ref2}. Recent studies have shown that primary human mesothelial cells respond to SV40 very differently from fibroblasts; the mesothelial cells are highly susceptible to SV40 infection and transformation. Most mesothelial cells were infected; few were killed; high levels of p53/T-ag complexes were present; Notch1, the hepatocyte growth factor receptor (Met), and IGF-1 were upregulated; and the tumor suppressor gene RASSF1A was inhibited^{ref1, ref2, ref3, ref4}. SV40-positive human mesotheliomas show similar changes. The rate of transformation of SV40-infected mesothelial cells was at least 1,000 times higher than that of human fibroblasts^ref. These findings emphasize that different human cell types may display dramatically different virus-cell interactions during infection
Transmission :

• the recognized natural hosts for SV40 are species of Asian macaque monkeys, especially the rhesus macaque (Macaca mulatta). SV40, like the polyomaviruses JCV and BKV, establishes persistent infections, often in the kidneys of susceptible hosts^{ref1, Lednicky, JA, 153-164}. An association of primary polyomavirus infection with mild respiratory tract disease, mild pyrexia, and transient cystitis has been reported^ref, but the route of infection of these 3 viruses has not been firmly defined. SV40 infections may become latent, and the level of virus present may be very low. Both viremia and viruria occur in infected animals, and virus shed in the urine is the probable means of transmission^{ref1, ref2}. SV40 infections in healthy monkeys appear to be asymptomatic^ref, but SV40 causes widespread infections among monkeys that are immunocompromised due to SIV infection^{ref1, ref2, ref3}; SV40 sequences and infectious virus were detected in brain, kidney, spleen, and peripheral blood mononuclear cells (PBMCs). These results demonstrate that SV40 can be an opportunistic pathogen in immunosuppressed hosts and that the virus may spread within the host by hematogenous routes. Zoonotic transmission of SV40 should be a consideration in certain populations. Indeed, laboratory workers in contact with SV40-infected monkeys and/or tissues from those animals had a prevalence of antibodies to SV40 in the range of 41 to 55%, suggesting an increased risk for viral infection among this group of workers^{ref1, ref2}. 25 of 109 of the North American zoo workers who had direct contact with primates (23%) tested positive for SV40, as compared with 15 of 145 workers (10%) who had no direct contact with primates. The mostly low-level of SV40 exposure observed in the workers suggests that there is no ongoing replication of SV40^ref. While humans who come into contact with primates may become infected with SV40, there is currently no evidence to suggest that SV40 has spread outside of zoo environments or that it plays a role in the development of cancer in humans.
• maternal-infant transmission is one possible route of SV40 spread in hamsters^ref. This may represent a pathway for SV40 infections in humans (of unknown frequency), as there are reports of the detection and expression of SV40 T-ag and the presence of viral DNA in cases of primary brain cancers in infants and young children^{ref1, ref2, ref3, ref4, ref5, ref6}
• SV40 contamination of polio vaccines : the discovery of the polyomavirus SV40, as well as its introduction as a pathogen into the human population, was tied to the development and worldwide distribution of early forms of the polio vaccine in the 1950's^{ref1, ref2}. Inactivated (Salk) and early live attenuated (Sabin) forms of polio vaccines were inadvertently contaminated with SV40^ref. In addition, different adenovirus vaccines distributed to some U.S. military personnel from 1961 to 1965 also contained SV40. The viral contamination occurred because these early vaccines were prepared in primary cultures of kidney cells derived from rhesus monkeys, which are often naturally infected with SV40^ref. Infectious SV40 survived the vaccine inactivation treatments, and conservative estimates indicate that up to 30 million people (children and adults) in the United States may have been exposed to live SV40 from 1955 through 1963 when administered potentially contaminated polio vaccines. Millions of people worldwide were also potentially exposed to SV40 because contaminated polio vaccines were distributed and used in many countries^ref. These data led the Institute of Medicine to conclude that "the biological evidence is of moderate strength that SV40 exposure from the polio vaccine is related to SV40 infection in humans". Shortly after its discovery, SV40 was shown to be a potent oncogenic DNA virus^ref. In animal models, the neoplasias induced by SV40 included primary brain cancers, malignant mesotheliomas, bone tumors, and systemic lymphomas^ref. Subsequently, many in vitro studies established that the oncogenic capacity of SV40 reflects the disruption of critical cell cycle control pathways^{ref1, ref2, ref3}. During the last decade, numerous published studies from independent laboratories, using different molecular biology techniques, have demonstrated SV40 large tumor antigen (T-ag) or DNA in primary human brain and bone cancers and malignant mesothelioma^{ref1, ref2, ref3, ref4}. More recently, studies have demonstrated that SV40 T-ag sequences are significantly associated with non-Hodgkin's lymphoma (NHL)^{ref1, ref2, ref3}. Therefore, the major types of tumors induced by SV40 in laboratory animals are the same as those human malignancies found to contain SV40 markers. A recent meta-analysis^ref of the molecular evidence conclusively established a significant excess risk of SV40 with those selected human cancers. It is noteworthy that SV40 has been detected in malignancies from children and young adults not exposed to contaminated polio vaccines, as well as in older adults^{ref1, ref2, ref3, ref4, ref5, ref6, ref7, ref8, ref9, ref10, ref11}. The detection of viral markers in young persons, by using molecular techniques, coupled with the isolation of infectious SV40 from tumors^ref and from nonneoplastic specimens^{ref1, ref2}, suggests that SV40 continues to cause infections in the human population today. In contrast, some retrospective epidemiological studies have failed to demonstrate an increased cancer risk in populations which had a high likelihood of having received potentially contaminated polio vaccine^{ref1, ref2, ref3, ref4}. However, the epidemiological data available are recognized to be inconclusive and limited^ref, and the Institute of Medicine found that the epidemiological data for cancer rates in people potentially exposed to SV40-contaminated vaccines are inadequate to evaluate a causal relationship. This conclusion is based on the lack of data on which individuals actually received contaminated vaccines, the unknown dosage of infectious SV40 present in particular lots of vaccine, the failure to know who among the exposed were successfully infected with SV40, the inability to know if the vaccine "unexposed" cohorts may have been exposed to SV40 from other sources, and the difficulty of monitoring a large population for cancer development for years after virus exposure. These important limiting factors led the Institute of Medicine to "not recommend additional epidemiological studies of people potentially exposed to contaminated polio vaccine." Although the prevalence of SV40 infections in humans is not known, studies conducted over the last 3 decades indicate that SV40 infections are occurring in child and adult populations today. These included individuals who received potentially SV40-contaminated vaccines, as well as in persons born after 1963 who could not have been exposed to those vaccines^{ref1, ref2, ref3, ref4, ref5, ref6, ref7, ref8, ref9, ref10, ref11, ref12, ref13, ref14, ref15, ref16, ref17, ref18, ref19, ref20, ref21, ref22, ref23, ref24, ref25, ref26, ref27, ref28, ref29, ref30, ref31, ref32, ref33, ref34, ref35, ref36, ref37, ref38, ref39, ref40}. In addition, 19% of newborn children and 15% of infants 3 to 6 months old at the time of receiving the oral contaminated polio vaccine were shown to excrete infectious SV40 in their stools for up to 5 weeks after vaccination^ref. It is important to point out that the incidence of SV40 infections linked to those vaccines is not known.

=> progressive multifocal leukoencephalopathy (PML) in AIDS patients. SV40 has been associated with a PML-like disease in rhesus monkeys. For this reason, perhaps, there is still concern that SV40 exposure by an atypical route may rarely result in late-developing disease in humans.

=> SV40 is a potent DNA tumor virus, and mounting evidence suggests that it is an emergent human pathogen^{ref1, ref2, ref3, ref4, ref5, ref6, ref7, ref8, ref9}. Recently, the Institute of Medicine of the National Academies concluded that "the biological evidence is strong that SV40 is a transforming virus" and that "the biological evidence is of moderate strength that SV40 exposure could lead to cancer in humans under natural conditions"^ref. In addition, 2 other independent scientific panels have made similar conclusions^{ref1, ref2}. A recent analysis suggested that SV40 should be included in the list of group 2A carcinogens (i.e., agents for which evidence is indicative but not definitive for carcinogenesis in humans) by the International Agency for Research on Cancer^ref. The oncogenic capacity of SV40 infections has been well established in laboratory animal models^{ref1, ref2, ref3, ref4}. The latent period of tumor development in hamsters infected with SV40 ranges from 3 months to > 1 year. Following intravenous inoculation, about 33% of the animals developed > 1 histologic type of neoplasm, with osteosarcomas being most common after lymphomas. Following intracardiac inoculation, malignant mesotheliomas and osteosarcomas developed in addition to lymphomas^ref. The frequency of tumor development is usually > 90% in animals infected as newborns but is reduced in older animals. These data suggest that the age at the time of infection, the route of infection, and the duration of infection may be factors influencing the development of malignancies by SV40. An etiologic role of the virus in those cancers was supported because SV40 T-ag was expressed in all malignant cells, animals with tumors developed antibody against SV40 T-ag, and neutralization of SV40 with specific antibody before virus inoculation prevented cancer development^{ref1, ref2}. Sequence analyses and detection of T-ag protein ruled out laboratory contamination of tumor samples. Importantly, infectious SV40 was isolated from a primary brain cancer of a 4-year-old child^ref. An important consideration when evaluating the molecular biology data is the sensitivity of methods used to detect SV40 in human tumor samples. Early studies (before 1992) identified SV40-positive neoplasms by using indirect immunofluorescence for viral proteins or DNA hybridization techniques^{ref1, ref2, ref3}, whereas studies after 1992 generally used PCR-based assays. During the last 3 decades > 60 original studies have reported the detection of SV40 in primary brain^ref and bone cancers, malignant mesothelioma^{ref1, ref2, ref3, ref4}, and NHL^{ref1, ref2}, whereas a few studies have described an absence of SV40 in those malignancies. However, the small numbers of samples tested, the histologic types of malignancies examined, and the laboratory methodologies employed in some cases limit the significance of the results in those studies reported to be negative. Indeed, several steps need to be considered when performing molecular studies of human specimens^{ref1, ref2, ref3}. First, the extraction step of nucleic acids determines whether tissues yield adequate and suitable DNA or RNA for analysis. Unfortunately, with formalin-fixed and paraffin-embedded specimens, degradation of nucleic acids and proteins is a common problem, and the quality of recovered DNA may be poor. If only small amounts of paraffin-embedded tissues are available, the yield of nucleic acids may be inadequate for analysis. Primers directed to a human cellular gene should be used to establish the suitability of a sample for PCR analysis. Because of the sensitivity of PCR-based assays, it is important to rigorously guard against laboratory contamination of samples and controls during processing or testing. Tissue processing and PCR assay setup should be performed in different facilities, from which positive controls (i.e., plasmids) are excluded. Negative tissue controls, extracted and analyzed in parallel, should be included in each experiment to monitor for reagent contamination. The selection of primers and PCR conditions greatly influences the sensitivity and reliability of the assay. Another factor is that tumor specimens usually contain mixtures of normal and malignant cells, in varying proportions. Variations in one or more of these important parameters may explain, at least in part, the ranges in positivity observed among some positive studies and the results obtained in some negative studies. Although numerous studies have detected SV40 in human primary brain and bone cancers, malignant mesothelioma, and NHL, the small sample sizes and the lack of a control group in some studies made it difficult to make conclusions about the extent to which SV40 may be associated with those human cancers. For this reason, we conducted a meta-analysis of controlled studies^ref, an approach which can provide a more balanced and less biased estimate of the evidence than individual studies^ref. For inclusion in the meta-analysis, reports had to meet the following criteria: studies were conducted among patients with primary malignancies, the investigation of SV40 was performed on primary cancer specimens and not on cultured cells, the analysis included a control group, and the same laboratory technique was used for both case and control samples. These criteria were established because the use of appropriate controls is crucial in the proper analysis of tissue for viral DNA, especially considering the sensitivity of PCR techniques^ref. 35 independent studies met these inclusion criteria. In total, data from 1,793 patients with primary malignancies were evaluated to determine whether SV40 is significantly associated with primary brain cancer, malignant mesothelioma, bone cancer, and NHL. The neoplasias induced by SV40 in animal models include^{ref1, ref2, ref3} :

• primary brain cancers : 13 human studies fulfilled the criteria for the investigation of primary brain cancers. The combined odds ratio (OR) of the studies used in the analysis was 3.9 (95% confidence interval [CI], 2.6 to 5.8). This effect was based on specimens from a total of 1,143 patients, of which 661 were primary brain cancer samples and 482 were control specimens. A modifier detected was the type of sample analyzed (paraffin embedded versus frozen). The adjusted OR was 3.8 (95% CI, 2.6 to 5.7)^ref.
• fibrillary astrocytomas
• anaplastic astrocytomas
• primary glioblastomas
• secondary glioblastomas derived thereof (59%)
• giant cell glioblastomas
• gemistocytic astrocytomas (32%)
• oligodendrogliomas (25%)
• gliosarcomas (11-25%)
• ependymomas (56%)
• choroid plexus papillomas (38%)
• medulloblastomas (29%)
• malignant mesothelioma (RASSF1A demethylation^{ref1, ref2, ref3, ref4}) : 15 human studies fulfilled the criteria; the combined OR of analysis was 16.8 (95% CI, 10.3 to 27.5) and was based on 528 patients with malignant mesothelioma and 468 controls. Modifiers detected were the type of control tissue and the method of detection of SV40. The adjusted OR was 15.1 (95% CI, 9.2 to 25.0)^{ref1, ref2, ref3, ref4}. Microdissection of human malignant mesothelioma samples followed by PCR detected SV40 T-ag DNA only in cancer cells and not in adjacent nonmalignant cells^{ref1, ref2}. SV40-like DNA sequences are present in mesotheliomas as well as in bronchopulmonary carcinomas and non-malignant pleuropulmonary diseases^ref.
• primary bone tumors : in human studies the combined OR of the analysis was 24.5 (95% CI, 6.8 to 87.9) and was based on 303 patients with bone tumors and 121 controls from 4 reports^ref
• osteosarcoma^{ref1, ref2, ref3, ref4, ref5}.
• systemic lymphomas : in hamsters inoculated intravenously with SV40, systemic lymphomas developed among 72% of the animals, compared to none in the control group^{ref1, ref2, ref3}. The lymphomas were of B-cell origin^ref. The OR for human non-Hodgkin's lymphomas (NHL) was 5.4 (95% CI, 3.1 to 9.3) and represented 301 cases and 578 controls included in 3 studies. Because there were only 3 studies that fulfilled the inclusion criteria, further examination of modifying variables was not possible for NHL^{ref1, ref2, ref3}.

This analysis of published reports found a significant excess risk of SV40 associated with human primary brain cancers, malignant mesotheliomas, bone cancers, and NHL compared to control samples. Therefore, the major types of human malignancies associated with SV40 are the same as those induced by SV40 in animal models. Although the proportion of human cancers containing SV40 varied from study to study, viral prevalence was always greater among primary tumors than among control tissues. Importantly, analysis of data indicated that SV40 may be etiologically meaningful in the development of a specific subset of human cancers. Multiple studies have shown the expression of SV40 mRNA and/or T-ag in cancer cells, the integration of SV40 sequences in some cancers, and SV40 T-ag protein complexed with p53 and pRb in some tumor specimens^{ref1, ref2, ref3, ref4, ref5, ref6}. These findings are compatible with current understanding of how SV40 T-ag mediates oncogenesis. These results from different experimental studies support the conclusion of the Institute of Medicine that "the biological evidence is of moderate strength that SV40 exposure could lead to cancer in humans under natural conditions." It has been reported that mesothelioma, brain tumors, osteosarcoma and non-Hodgkin lymphoma (NHL) contain SV40 DNA sequences and that SV40 infection introduced into humans by the vaccine probably contributed to the development of these cancers. The Immunization Safety Review Committee of the Institute of Medicine (IOM) reviewed this topic in 2002. The present review of recent studies showed that the earlier results describing the recovery of SV40 DNA sequences from a large proportion of the above tumors were not reproducible and that most studies were negative. Contamination with laboratory plasmids was identified as a possible source of false positive results in some previous studies. The low-level immunoreactivity of human sera to SV40 was very likely the result of cross-reactivity with antibodies to the SV40-related human polyomaviruses BKV and JCV, rather than of authentic SV40 infection. SV40 sero-reactivity in patients with the suspect tumors was no greater than that in controls. In epidemiologic studies, the increased incidence of some of the suspect tumors in the 1970s to 1980s was not related to the risk of exposure to SV40-contaminated vaccines. In summary, the most recent evidence does not support the notion that SV40 contributed to the development of human cancers^ref
 

Laboratory examinations : positive tests for an immune response to SV40, as measured by the presence of antibodies against SV40, in human blood samples may actually represent a cross-reaction with antibodies to BKV or JCV, 2 common human viruses.